Viking Therapeutics Shares Surge Up to 39% on Positive Weight-Loss Drug Maintenance Data

 And that very fear has wrapped the second wave of the GLP-1 drug race, not on the question of if it works, but rather whether it maintains effectiveness as the patient attempts to reduce its dosage.

On Tuesday, Viking Therapeutic finally provided an answer to that concern, and based on the company performance on the stock market, it was a fairly promising one! Viking Therapeutics (Listed NASDAQ: VKTX) witnessed a massive surge of nearly 38-39% in the premarket and morning trading levels before finishing the day with a 35.7% final gain and a price of $40.85, marking the largest one-day surge and high it had witnessed over the past two years. The surge was based on Viking’s published topline data of its experimental obesity drug - the VK2735 which successfully protected the weight loss of patients despite the patients shifting from weekly injections to a less frequent maintenance schedule.

Table of Contents

1. What the Trial Actually Found

2. The Numbers, Broken Down

3. Why "Maintenance" Data Matters So Much Right Now

4. How Wall Street Reacted

5. Where VK2735 Fits in the Broader Obesity Drug Race

6. What's Still Unknown

7. Conclusion

What the Trial Actually Found

Viking’s Phase 2 Study was conducted over 180 people with obesity who reported no other related health conditions and were randomized into one of the four VK2735 dosing regimens or into the placebo group over a primitive 21-week treatment period. Following the completion of the induction phase, the participants were then switched onto a lesser intense schedule with lesser injections, either alternating between weeks or being administered once a week for a further period of 12 weeks.

The VK2735 drug is agonist in nature, meaning it focuses on both the GLP-1 and the GIP receptor cells involved in the appetite regulation, a similar functioning to the general class drugs of Novo Nordisk's Wegovy and Eli Lilly's Zepbound, despite a unique dosing profile. Throughout the study, the drug users reported complaints that are typical of the drug class - mainly Gastrointestinal side effects while placing the intensity of such complaints at typical levels during the maintenance phases. Overall, the VK2735 drug received an “impressively clean” rating profile on the parameters of its overall safety and tolerability by the Leerink Partners analyst Thomas Smith.

The Numbers, Broken Down

The market reactions were of significant measure since the company’s results headlined across multiple aspects. And amidst these details, the maintenance data of the patients is one to look out for. The published results claimed that patients who stepped down to an injection every alternate week retained an average of 90% of the weight they had lost while the once-monthly group retained a rough average of 85%, a steep rise from the 61% retention observed within the placebo group. Why the numbers matter so strongly is based on the fact that the drugs maintain their effectiveness strongly, regardless of the patient choosing a weekly or a monthly dosing treatment approach for themselves.

Why "Maintenance" Data Matters So Much Right Now

It's worth emphasizing on why this set of data is more significant than any previous phase or result that failed to create an impact on the stock market of such magnitude. The GLP-1 Obesity Drug Category in documented history has always struggled with an adherence problem amongst its consumers, with patients that are supposed to be on weekly treatments, often drop out or discontinue treatment after securing their target goal, only to quickly regain it afterwards. VK2735’s ability to maintain the results after transition into a lighter dose addresses that very gap, focusing on longevity of results instead of mere extensive capacity of causing weight loss.

Viking's CEO, Brian Lian, while addressing the success of the results emphasized on the company’s belief that long-term consistent weight management for the future will require individual programs instead of the current one-size-fits-all approach and the company is committed to cater to that very need for its clients. Louis Aronne, former president of The Obesity Society and a professor at Weill Cornell Medical College, also provided direction along the same lines while reiterating the idea of dosing flexibility being essential to achieving the kind of treatment persistence needed for long-term weight control.

How Wall Street Reacted

Following the release of its successful Phase 2 Trials, VKTX shares began with a significant high above their previous day’s close while soaring up to 38-39% during the day and settling at a 35.7% rise at $40.85, marking the company’s best single-day performance since February 2024, while also taking the valuation higher than its 5-day moving average for the first time in more than a month.

Where VK2735 Fits in the Broader Obesity Drug Race

Viking’s VK2735 is gearing up to enter a market that looks set to bloom over the coming years, aligning the drug’s current timeline along with the global increase in drug need. Goldman Sachs Research has also projected a $114 billion market by the year 2030, with the market currently being dominated by two drugs, Novo Nordisk's Wegovy and Eli Lilly's Zepbound that are also gearing up for impact by Viking VK2735. VK2735 is being developed in both injectable and oral formulations, and is currently in Phase 3 testing across two fully enrolled trials involving roughly 5,500 patients combined, under Viking's "Vanquish" program.

Considering that Viking Therapeutics continue to remain as a clinical-stage biopharmaceutical company that is working to establish a foothold against two much larger, already-approved competitors, Tuesday's data is being received as a testament that VK2735 would not simply rely on efficacy but also attempting to include client convenience and long-term adherence for suitable treatment approach.

What's Still Unknown

While the Phase 2 Success continues to echo throughout the industry, there are some important factors to consider, with the current results originating from a Phase 2 maintenance study and Vikings needing similar results in the Phase 3 Data results as they are usually the benchmark for regulatory approval. Viking is currently undergoing Phase 3 Vanquish trials, with more number of patients and greater importance of the outcome in front of the FDA. As things stand, the company hasn’t established a notable timeline for the trial phases or regulatory submission but instead has highlighted its plans to conduct oral maintenance dosing regime-focused trials during the later stages, while leaving room for the consistency and maintenance results with the oral formulation. And as it is common amongst GLP-1 Drug Class, it is important to proceed with caution on successful results as early positive results often fail to be consistent amongst the more larger and diverse populations of the phase 3 trials, a notable pattern that has also been witnessed within some of Viking’s own previous trials.

Conclusion

It is important to practise a bit of caution before entirely relying on the stock surges of Phase 2 especially considering how many promising drugs often begin plummeting down during Phase 3 or FDA Security testing periods. Yet, it is also crucial to consider that Viking’s VK2735 didn't simply showcase that the drug works, but rather proved that it holds effectiveness, even when patients decide to reduce their consumption or shift to a lower treatment regime - the gap that the GLP-1 Category Drugs have failed to fulfill over the past decade. Now whether VK2735 further builds onto this momentum and promises to the markets that is currently dominated by two fierce competitors, or rather plummets during the future trials is an open question that the entire world awaits an answer to eagerly.

This article is for informational purposes only and does not constitute financial or medical advice. Clinical trial results discussed here are topline findings from the company and have not yet been peer-reviewed or published in full; consult a healthcare provider for guidance on obesity treatment options, and a financial advisor before making investment decisions.